1

IDegAsp (Ryzodeg®)
Experience-in-Action 2018
(REAXN)

Case Sharing

IDegAsp = Insulin Degludec/Insulin Aspart

PH/RY/0418/0119
Disclosures

• This Continuing Medical Education is sponsored by Novo Nordisk

Pharmaceuticals (Philippines), Inc. (“Novo Nordisk”).

• Speaker/presenter has been financially supported (e.g., honoraria)

by Novo Nordisk.

• Any other financial interests and arrangements of the

speaker/presenter:
• Etc.

This material is for preparatory internal use in NN only

PH/NM30/1116/0066
Instructions to the presenter

• Given below are some template slides which you may use to present a
clinical case for the discussion. Guide questions are also provided to
facilitate the discussion.

• Kindly include patient cases that cover the topic of insulin intensification.

• As a review, you may also request and include articles to aid in the case
sharing session.

• Please include as many intensification cases for discussion as the time for
the activity will allow.

This material is for preparatory internal use in NN only

PH/NM30/1116/0066
 Patient Profile
Initials Input Text Here

Age, Sex & Occupation ## M/F

Diagnosis Type # diabetes mellitus for ## years

PPG ### mg/dL FPG ### mg/dL HbA1c #.#%

• eGFR, lipid profile, BMI, etc.

Other pertinent labs

• Medication 1
• Medication 2
Current • Medication 3
medications • Medication 4
• Medication 5
• Medication 6

This material
PPG: Post Prandial Glucose; FPG: Fasting Plasma Glucose; HbA1c: Hemoglobin is for
A 1c; eGFR: preparatory
estimated internal
glomerular use inrate;
filtration NN only
BMI: Body Mass Index
Patient Profile
Initials Input Text Here

Age and Sex ## M/F

• Text
• Text
• Text

Other pertinent
information
about the case

This material is for preparatory internal use in NN only

Patient Profile
Initials Input Text Here

Age and Sex ## M/F

• How did you intensify your patient from the previous

insulin regimen to Insulin Degludec/Insulin Aspart?
• How did you titrate the dose?
• What factors led you to your therapeutic decision of
intensifying to Insulin Degludec/Insulin Aspart from
the previous insulin?
Initial
Management

This material is for preparatory internal use in NN only

 Patient Profile
Initials Input Text Here

Age and Sex ## M/F

• Latest laboratory results: PPG, FPG, HbA1c

• SMBG monitoring results, if any
• Plan for optimization of treatment, if required or
being considered
• What improvements in the patient’s clinical status did
you observe?
Follow-up • What were your other observations on treatment with
Insulin Degludec/Insulin Aspart?
• What was the patient’s feedback on the treatment
and device?

This material
PPG: Post Prandial Glucose; FPG: Fasting Plasma Glucose; HbA1c: Hemoglobin is for
A 1c; SMBG: preparatory internal
Sel-monitoring of Blood use in NN only
Glucose
 8

Q&A

This material is for preparatory internal use in NN only

 9

This material is for preparatory internal use in NN only